Market: NASD |
Currency: USD
Address: 121 South Orange Avenue
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
📈 Nutriband Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$15.00
-
Upside/Downside from Analyst Target:
133.10%
-
Broker Call:
2
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
10-25%
-
Upcoming Earnings Date:
-
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2022 |
- |
$1.166000 |
- |
2022-08-12 |
- |
Stock split |
|
Total Amount for 2022: $1.166000 |
📅 Earnings & EPS History for Nutriband Inc.
| Date | Reported EPS |
|---|
| 2025-05-30 | -0.12 |
| 2025-04-28 | -0.51 |
| 2023-04-26 | -0.17 |
| 2022-12-02 | -0.14 |
| 2022-09-08 | -0.12 |
| 2022-05-31 | -0.08 |
| 2022-04-29 | -0.19 |
| 2021-12-14 | -0.23 |
| 2021-09-03 | -0.07 |
| 2021-06-14 | -0.05 |
| 2021-04-02 | -0.33 |
| 2020-12-15 | -0.01 |
| 2020-09-11 | -0.03 |
| 2020-06-04 | -0.06 |
| 2020-04-14 | -0.11 |
| 2019-12-12 | -0.05 |
| 2019-09-13 | -0.07 |
| 2019-06-13 | -0.1 |
| 2019-04-19 | -0.1 |
| 2018-12-14 | -0.07 |
📰 Related News & Research
No related articles found for "nutriband inc".
